NEW YORK, May 26, 2011 /PRNewswire/ — Lpath, Inc. (OTCBB:
LPTN), the industry leader in lipidomics-based therapeutics, will
present on RetailInvestorConferences.com on June 2, 2011 at 1:00 PM
EDT.
Lpath’s president and CEO, Scott Pancoast, will discuss the
company’s progress, including status updates on the PEDigree and
Nexus clinical trials, where the company’s ocular drug candidate,
iSONEP™, is being investigated in human proof-of-concept
studies.
To access, follow this link: www.retailinvestorconferences.com
and then click on: “Register/Watch Event Now!” Attendees are
advised to pre-register and receive event updates.
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time in the
virtual “presentation hall.” After the presentation investors are
invited to ask questions and download shareholder materials from
the company’s “virtual booth.” A replay of the event will be
available for 90 days.
Lpath entered into an agreement with Pfizer in late 2010 that
provides Pfizer an exclusive option for a worldwide license to
develop and commercialize iSONEP for ocular indications. Pfizer and
Lpath are collaborating closely on the two iSONEP clinical
trials.
Pfizer also has a right of first refusal, which expires in late
2013, for Lpath’s cancer drug candidate, ASONEP™. Lpath is
planning to further investigate ASONEP in a Phase 2 trial involving
renal cell carcinoma patients and perhaps in a second trial
involving patients with prostate cancer or neuroblastoma.
About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the
category leader in lipidomics-based therapeutics, an emerging field
of medicine that targets bioactive signaling lipids for treating a
wide range of human disease. Lpath’s ImmuneY2™ drug-discovery
engine has the unique ability to generate therapeuti
‘/>”/>
SOURCE
